Several hopefuls before admission Such so-called dampening immunomodulators, which slow down an excessive immune reaction, could increasingly come onto the market in the near future. Vfa spokesman Hömke refers to several agents that are in phase III and which, if the positive interim results are confirmed, could be submitted for approval in the next few months. These include the MK-7110 from MSD, Leronlimab from CytoDyn and Siltuximab from Eusa Pharma. German companies are also in the running here. The Jena-based company InflaRx is testing in a phase II / III study whether the agent vilobelimab can help Covid-19 seriously ill people. And the German-American Immunic Therapeutics is testing its IMU-838 immunomodulator in two Phase II studies with inpatient corona patients.
News 
Market Data 
Discover 
